


## Atorvastatin hemicalcium salt

<b>Cat. No.:</b>	HY-17379
<b>CAS No.:</b>	134523-03-8
<b>Molecular Formula:</b>	C <sub>33</sub> H <sub>34</sub> Ca <sub>0.5</sub> FN <sub>2</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	577.67
<b>Target:</b>	HMG-CoA Reductase (HMGCR); Autophagy; Ferroptosis
<b>Pathway:</b>	Metabolic Enzyme/Protease; Autophagy; Apoptosis
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (86.55 mM)  
 H<sub>2</sub>O : < 0.1 mg/mL (insoluble)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7311 mL	8.6555 mL	17.3109 mL
	5 mM	0.3462 mL	1.7311 mL	3.4622 mL
	10 mM	0.1731 mL	0.8655 mL	1.7311 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (4.33 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (4.33 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC<sub>50</sub>s of 0.39 μM and 2.39 μM, respectively<sup>[1][2][3]</sup>.

#### In Vitro

Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation<sup>[4]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE<sup>-/-</sup> mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE<sup>-/-</sup> mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1 $\beta$  are all remarkably inhibited after Atorvastatin treatment<sup>[5]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Forty 8-week-old ApoE <sup>-/-</sup> mice induced with angiotensin II (Ang II) <sup>[5]</sup>
Dosage:	20 mg/kg, 30 mg/kg
Administration:	Oral gavage; once a day; for 28 days
Result:	Significantly reduced ER stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE <sup>-/-</sup> mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1 $\beta$ were all remarkably inhibited

## CUSTOMER VALIDATION

- Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.
- Oncogene. 2022 Oct 31.
- Cancer Lett. 2022 Oct 19;215976.
- Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658.
- Cell Death Dis. 2021 May 13;12(5):482.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22.
- [2]. Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.
- [3]. Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.
- [4]. Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72.
- [5]. Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA